United StatesThe U.S. Food and Drug Administration (FDA) has approved Replimune's melanoma treatment, RP1 (marketed as Tudriqev), after a lengthy and contentious approval process. The decision follows a recent advisory committee vote supporting the drug, despite internal FDA staff concerns about the trial's design. This marks a significant victory for the biotech company and patient advocates who had been pushing for approval. The FDA granted accelerated approval based on evidence of potential efficacy and the urgent need for new treatments. Replimune has not yet announced the drug's pricing.
Bias read (Center): The article presents the FDA's decision as a balanced outcome, acknowledging both the agency's concerns and the advisory committee's support. It does not overtly favor either the biotech company or regulatory authorities, nor does it frame the issue in a clearly partisan manner. The focus remains on
